COVID-19与精神障碍的双向关联:美国62 354例回顾性队列研究
该研究利用美国TriNetX电子健康记录网络69·8百万患者数据,纳入62 354例COVID-19患者,采用倾向评分匹配分析COVID-19与后续精神障碍诊断的双向关联。发现无精神病史者感染COVID-19后14-90天新发精神障碍风险较其他健康事件升高(HR 1·6-2·2),既往精神障碍诊断与COVID-19风险升高相关(RR 1·65)。
要点
- COVID-19幸存者14-90天新发精神障碍风险升高,焦虑、失眠和痴呆风险最高。
- 既往一年内有精神障碍诊断者COVID-19风险升高(RR 1·65),独立于已知躯体风险因素。
- 65岁以上COVID-19患者14-90天新发痴呆诊断发生率为1·6%。
核心结论
- COVID-19幸存者似乎精神后遗症风险增加,精神障碍诊断可能是COVID-19的独立风险因素。
- 研究结果为临床服务提供启示,但需前瞻性队列研究验证。
研究设计与样本
- 电子健康记录网络队列研究,使用TriNetX Analytics Network,覆盖美国54家医疗机构69·8百万患者。
- 纳入2020年1月20日至8月1日诊断的62 354例COVID-19患者,采用倾向评分匹配控制COVID-19风险因素和疾病严重程度混杂。
- 测量COVID-19诊断后14-90天精神障碍、痴呆和失眠的发生率和风险比(HR)。
主要发现
- 无精神病史患者中,COVID-19诊断后14-90天新发精神障碍诊断风险较流感升高(HR 2·1,95%CI 1·8-2·5),较其他呼吸道感染升高(HR 1·7,95%CI 1·5-1·9),较皮肤感染升高(HR 1·6,95%CI 1·4-1·9),较胆结石升高(HR 1·6,95%CI 1·3-1·9),较泌尿系结石升高(HR 2·2,95%CI 1·9-2·6),较大骨骨折升高(HR 2·1,95%CI 1·9-2·5),所有p<0·0001。
- 焦虑障碍、失眠和痴呆的HR最高。
- COVID-19诊断后14-90天任何精神障碍诊断发生率为18·1%(95%CI 17·6-18·6),其中5·8%(95%CI 5·2-6·4)为首诊。
- 65岁以上人群COVID-19诊断后14-90天新发痴呆诊断发生率为1·6%(95%CI 1·2-2·1)。
- 既往一年内有精神障碍诊断与COVID-19诊断发生率升高相关(相对风险1·65,95%CI 1·59-1·71;p<0·0001),独立于已知躯体健康风险因素。
临床怎么用
- 对COVID-19幸存者应关注焦虑、失眠和痴呆等精神后遗症,尤其在感染后14-90天。
- 对有精神障碍病史者应警惕其COVID-19风险升高,考虑纳入感染预防关注人群。
局限性
- 不能排除社会经济因素等残余混杂。
- 研究为回顾性队列,结果属初步,需前瞻性队列研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse mental health consequences of COVID-19, including anxiety and depression, have been widely predicted but not yet accurately measured. There are a range of physical health risk factors for COVID-19, but it is not known if there are also psychiatric risk factors. In this electronic health record network cohort study using data from 69 million individuals, 62 354 of whom had a diagnosis of COVID-19, we assessed whether a diagnosis of COVID-19 (compared with other health events) was associated with increased rates of subsequent psychiatric diagnoses, and whether patients with a history of psychiatric illness are at a higher risk of being diagnosed with COVID-19. METHODS: We used the TriNetX Analytics Network, a global federated network that captures anonymised data from electronic health records in 54 health-care organisations in the USA, totalling 69·8 million patients. TriNetX included 62 354 patients diagnosed with COVID-19 between Jan 20, and Aug 1, 2020. We created cohorts of patients who had been diagnosed with COVID-19 or a range of other health events. We used propensity score matching to control for confounding by risk factors for COVID-19 and for severity of illness. We measured the incidence of and hazard ratios (HRs) for psychiatric disorders, dementia, and insomnia, during the first 14 to 90 days after a diagnosis of COVID-19. FINDINGS: In patients with no previous psychiatric history, a diagnosis of COVID-19 was associated with increased incidence of a first psychiatric diagnosis in the following 14 to 90 days compared with six other health events (HR 2·1, 95% CI 1·8-2·5 vs influenza; 1·7, 1·5-1·9 vs other respiratory tract infections; 1·6, 1·4-1·9 vs skin infection; 1·6, 1·3-1·9 vs cholelithiasis; 2·2, 1·9-2·6 vs urolithiasis, and 2·1, 1·9-2·5 vs fracture of a large bone; all p<0·0001). The HR was greatest for anxiety disorders, insomnia, and dementia. We observed similar findings, although with smaller HRs, when relapses and new diagnoses were measured. The incidence of any psychiatric diagnosis in the 14 to 90 days after COVID-19 diagnosis was 18·1% (95% CI 17·6-18·6), including 5·8% (5·2-6·4) that were a first diagnosis. The incidence of a first diagnosis of dementia in the 14 to 90 days after COVID-19 diagnosis was 1·6% (95% CI 1·2-2·1) in people older than 65 years. A psychiatric diagnosis in the previous year was associated with a higher incidence of COVID-19 diagnosis (relative risk 1·65, 95% CI 1·59-1·71; p<0·0001). This risk was independent of known physical health risk factors for COVID-19, but we cannot exclude possible residual confounding by socioeconomic factors. INTERPRETATION: Survivors of COVID-19 appear to be at increased risk of psychiatric sequelae, and a psychiatric diagnosis might be an independent risk factor for COVID-19. Although preliminary, our findings have implications for clinical services, and prospective cohort studies are warranted. FUNDING: National Institute for Health Research.
引用
- Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2020. PMID: 33181098. doi:10.1016/S2215-0366(20)30462-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。